2N Pharma has developed a new approach to treating ALS by addressing a shared pathogenic mechanism found in several neurological disorders. Their research has shown promising results, leading to the development of therapeutic drug candidates for ALS, Huntington's, Parkinson's, and SPMS. The company aims to make a positive difference in the lives of patients by translating their research into effective medications.